

Reference number(s)
1654-A

SPECIALTY GUIDELINE MANAGEMENT

CINQAIR (reslizumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.

Limitations of Use:

- Not for treatment of other eosinophilic conditions
- Not for the relief of acute bronchospasm or status asthmaticus

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Authorization of 12 months may be granted for treatment of asthma when all of the following criteria are met:

- A. Member is 18 years of age or older.
- B. Member has baseline blood eosinophil count of at least 400 cells per microliter.
- C. Member has inadequate asthma control (e.g., hospitalization or emergency medical care visit within the past year) despite current treatment with both of the following medications at optimized doses:
 1. Inhaled corticosteroid
 2. Additional controller (long acting beta₂-agonist, leukotriene modifier, or sustained-release theophylline)

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for treatment of asthma when all of the following criteria are met:

- A. Member is 18 years of age or older.
- B. Asthma control has improved on Cinqair treatment as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations.

IV. REFERENCES

1. Cinqair [package insert]. Frazer, PA: Teva Pharmaceuticals, Inc.; May 2016.
2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med.* 2015;3(5):355-366.

Reference number(s)
1654-A

3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2018 update. <http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/>. Accessed March 23, 2018.